Non-Viral
Approaches
Multiple modalities to treat neurological diseases.
Monoclonal Antibodies
The Voyager team has discovered multiple antibodies as part of the anti-tau antibody program and other research programs. Some of these programs have been advanced in a vectorized setting, such as the anti-amyloid beta program, while others have been advanced in a non-vectorized setting, such as the anti-tau antibody program.
VYGR-NeuroShuttle: Next-Gen Approach to Neurotherapeutics
Voyager NeuroShuttle™ (VYGR-NeuroShuttle) is a non-viral delivery platform leveraging novel receptor-binding molecules to transport multiple modalities of neurotherapeutics across the blood-brain barrier (BBB).
Platform optimization and program development across therapeutic modalities ongoing, in rodents and non-human primates.
How It Works:
Multiple potential opportunities for Voyager’s NeuroShuttle platform to create value:
- Increase efficacy by increasing on-target delivery
- Improve safety by reducing peripheral exposure
- Lower COGS by reducing dose needed
- Expand opportunity for shuttles: ALPL first of multiple receptors identified